Dyne Therapeutics Inc (DYN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Dyne Therapeutics Inc stock (DYN) is currently trading at $17.85. Analyst consensus price target for DYN is $38.19. WallStSmart rates DYN as Sell.
- DYN PE ratio analysis and historical PE chart
- DYN PS ratio (Price-to-Sales) history and trend
- DYN intrinsic value — DCF, Graham Number, EPV models
- DYN stock price prediction 2025 2026 2027 2028 2029 2030
- DYN fair value vs current price
- DYN insider transactions and insider buying
- Is DYN undervalued or overvalued?
- Dyne Therapeutics Inc financial analysis — revenue, earnings, cash flow
- DYN Piotroski F-Score and Altman Z-Score
- DYN analyst price target and Smart Rating
Dyne Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Dyne Therapeutics Inc (DYN) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, institutional own.. Concerns around return on equity. Significant fundamental concerns warrant caution or avoidance.
Dyne Therapeutics Inc (DYN) Key Strengths (3)
Growing significantly faster than its price suggests
115.14% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Dyne Therapeutics Inc (DYN) Areas to Watch (2)
Company is destroying shareholder value
Fairly priced relative to book value
Dyne Therapeutics Inc (DYN) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 3 register as strengths (avg 9.0/10) while 2 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Institutional Own., Market Cap. Valuation metrics including PEG Ratio (0.19) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Price/Book. Some valuation metrics including Price/Book (2.98) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -55.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -55.70% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DYN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
DYN's Price-to-Sales ratio of 5.08x sits near its historical average of 5.5x (56th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 66% below its historical high of 15x set in Aug 2024, and 218% above its historical low of 1.6x in May 2022. Over the past 12 months, the PS ratio has expanded from ~3.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Dyne Therapeutics Inc (DYN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Dyne Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -112M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Dyne Therapeutics Inc.
Bottom Line
Dyne Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(18 last 3 months)
| Insider | Type | Shares |
|---|---|---|
KERSTEN, DIRK Director | Sell | -177,690 |
| Insider | Type | Shares |
|---|---|---|
POSNER, BRIAN S Director | Buy | +3,000 |
Data sourced from SEC Form 4 filings
Last updated: 8:22:28 AM
About Dyne Therapeutics Inc(DYN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The company is headquartered in Waltham, Massachusetts.